Kathy Gaddes - AmerisourceBergen Ex Officer
ABG Stock | EUR 234.55 0.10 0.04% |
Insider
Kathy Gaddes is Ex Officer of AmerisourceBergen
Age | 60 |
Phone | 610 727 7000 |
Web | https://www.amerisourcebergen.com |
AmerisourceBergen Management Efficiency
The company has return on total asset (ROA) of 0.0294 % which means that it generated a profit of $0.0294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.502 %, meaning that it generated $0.502 on every $100 dollars invested by stockholders. AmerisourceBergen's management efficiency ratios could be used to measure how well AmerisourceBergen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | INSIDER Age | ||
Wanyong Lian | Sinopharm Group Co | 52 | |
Ronald South | Henry Schein | 61 | |
Stephen Mason | Cardinal Health | 51 | |
Jessica Mayer | Cardinal Health | 53 | |
Michelle Greene | Cardinal Health | N/A | |
Patricia English | Cardinal Health | 43 | |
Xiuchang Jiang | Sinopharm Group Co | 59 | |
Olga Timoshkina | Henry Schein | N/A | |
Stanley Bergman | Henry Schein | 73 | |
Yaohua Zhang | Shanghai Pharmaceuticals Holdin | 45 | |
Yongzhong Li | Shanghai Pharmaceuticals Holdin | 53 | |
Christine Sacco | Prestige Consumer Healthcare | 47 | |
Ying Ke | Shanghai Pharmaceuticals Holdin | N/A | |
Walter Siegel | Henry Schein | 63 | |
Kevin Pohlman | Patterson Companies | 59 | |
Maisong Cai | Sinopharm Group Co | 53 | |
Chaoyang Gu | Shanghai Pharmaceuticals Holdin | 53 | |
Yong Liu | Sinopharm Group Co | 54 | |
James Breslawski | Henry Schein | 69 | |
Dawei Liu | Shanghai Pharmaceuticals Holdin | 38 | |
Michael Ettinger | Henry Schein | 62 |
Management Performance
Return On Equity | 0.5 | |||
Return On Asset | 0.0294 |
AmerisourceBergen Leadership Team
Elected by the shareholders, the AmerisourceBergen's board of directors comprises two types of representatives: AmerisourceBergen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AmerisourceBergen. The board's role is to monitor AmerisourceBergen's management team and ensure that shareholders' interests are well served. AmerisourceBergen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AmerisourceBergen's outside directors are responsible for providing unbiased perspectives on the board's policies.
PharmD Mauch, Ex COO | ||
Steven Collis, Pres Chairman | ||
Kathy Gaddes, Ex Officer | ||
James Cleary, Ex CFO | ||
Elizabeth Campbell, Ex Officer | ||
Bennett Murphy, VP Relations | ||
Silvana Battaglia, Ex Officer | ||
Lazarus Krikorian, Chief VP | ||
John Chou, Ex CEO | ||
Gina Clark, Exec Officer |
AmerisourceBergen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AmerisourceBergen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.5 | |||
Return On Asset | 0.0294 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.01 % | |||
Current Valuation | 33.88 B | |||
Shares Outstanding | 202.26 M | |||
Shares Owned By Insiders | 16.95 % | |||
Shares Owned By Institutions | 77.85 % | |||
Price To Earning | 17.93 X | |||
Price To Book | 5.05 X |
Currently Active Assets on Macroaxis
Other Information on Investing in AmerisourceBergen Stock
AmerisourceBergen financial ratios help investors to determine whether AmerisourceBergen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AmerisourceBergen with respect to the benefits of owning AmerisourceBergen security.